The global sepsis therapeutics market size was estimated at USD 3.94 billion in 2024 and is anticipated to grow at a CAGR of 6.18% from 2025 to 2030. The rising prevalence of sepsis, driven by factors such as hospital-acquired infections, surgical complications, and the increasing number of critically ill patients, is fueling demand for sepsis therapeutics. The growing awareness regarding the early detection and timely treatment of sepsis, along with advancements in diagnostic tools, is further contributing to market expansion.
Sepsis remains one of the leading causes of death globally, yet reliable population-level data collection remains a challenge. According to the World Health Organization (WHO) data published in 2020, there were 48.9 million sepsis cases and 11 million sepsis-related deaths worldwide, accounting for 20% of all global deaths. Notably, nearly half of these cases (20 million) occurred in children under the age of five. As a result, there is an increasing emphasis on developing innovative therapies, diagnostic tools, and protocols to reduce the global burden of sepsis, which is expected to propel the growth of the sepsis therapeutic market in the coming years.
Additionally, the surge in sepsis-related research and development, along with strong collaboration between pharmaceutical companies and academic institutions, is leading to the introduction of new and innovative therapies. Government initiatives and funding aimed at improving healthcare infrastructure and access to advanced treatments are also helping to accelerate market growth. These factors combined are driving the continued evolution of the sepsis therapeutics industry.
In September 2023, the International Center for Clinical Research (ICRC) at St. Anne’s University Hospital launched the “BEATSep” research consortium, funded by HORIZON EUROPA with 7.10 million USD over five years. The project focuses on understanding the cellular and molecular mechanisms behind immune suppression in sepsis survivors. This initiative could significantly impact the sepsis therapeutic market by leading to the development of targeted therapies that address long-term immune dysfunction in sepsis survivors, thereby improving patient outcomes and expanding treatment options.
The sepsis therapeutics market is highly innovative, driven by advancements in novel antibiotics, immunomodulatory therapies, and precision medicine. Breakthroughs in biologics, AI for sepsis prediction, and rapid diagnostics are enhancing treatment options and improving patient outcomes.
The market experiences a significant amount of mergers and acquisitions (M&A) activity, as large pharmaceutical companies look to expand their sepsis portfolios and leverage the expertise of specialized biotech firms. M&A activities are primarily driven by the need to acquire innovative therapies, such as novel anti-infective drugs, immune modulators, and sepsis-specific diagnostics.
Regulatory frameworks have a profound influence on the market for sepsis therapeutics. Regulatory agencies such as the FDA and EMA play a critical role in the approval of new drugs, with stringent safety and efficacy standards that ensure patient well-being. However, these regulations can also result in long approval timelines, which may delay the availability of new therapies. In addition, reimbursement policies significantly impact market access, with healthcare systems in both developed and emerging markets needing to balance cost-effectiveness with patient access to lifesaving treatments.
Product substitutes present a moderate challenge in the sepsis therapeutics industry, primarily in the form of traditional treatments like antibiotics, vasopressors, and supportive care measures. While these approaches remain vital, they often do not fully address the complex nature of sepsis and its underlying causes. As a result, the development of adjunctive therapies, including immunomodulators, novel antimicrobials, and sepsis biomarkers, is vital to enhancing treatment efficacy.
Geographical expansion is a key strategy for the players in the sepsis therapeutics market, particularly as the demand for innovative sepsis treatments grows worldwide. Companies are increasingly targeting regions with high sepsis-related mortality rates, such as Southeast Asia, Latin America, and parts of Africa, where access to effective treatments is limited.
The cephalosporin segment accounted for the largest revenue share of 60.70% in 2024, due to their broad-spectrum activity against gram-positive and gram-negative bacteria, which makes them a preferred choice in the treatment of sepsis. Their effectiveness, coupled with their ability to be used in a wide range of clinical settings, supports their leading role in sepsis management. The continued development of newer generations of cephalosporins with enhanced activity against resistant pathogens further strengthens the demand for these antibiotics in sepsis therapy.
The glycopeptide segment is expected to exhibit the fastest CAGR over the forecast period. Glycopeptides, such as vancomycin, are primarily used in the treatment of infections caused by resistant gram-positive organisms, including MRSA (methicillin-resistant Staphylococcus aureus). The increasing prevalence of antibiotic-resistant infections is driving the need for effective and targeted glycopeptide therapies. As resistance to traditional antibiotics continues to rise, the demand for glycopeptides in sepsis treatment is anticipated to accelerate
The parenteral segment captured the largest revenue share at 65.75% in 2024 and is expected to grow at the fastest CAGR over the forecast period. Parenteral administration, particularly intravenous (IV) delivery, is preferred for sepsis management due to its rapid onset of action and high bioavailability, ensuring that critical patients receive immediate therapeutic benefits. Given the urgency and severity of sepsis, parenteral administration allows for precise dosing and fast delivery of antibiotics directly into the bloodstream, which is essential for the treatment of life-threatening infections. This route is expected to continue leading the market as it remains the gold standard for sepsis treatment in emergencies and intensive care settings.
The oral route of administration segment is anticipated to witness the fastest CAGR during the forecast period. The growth of this segment is driven by the growing demand for convenient, outpatient treatment options for patients recovering from sepsis. Oral antibiotics offer an effective alternative to intravenous therapies, especially for less severe cases or when transitioning patients from hospital to home care. With the rise in antimicrobial resistance, there is a focus on developing oral antibiotics that are effective against resistant strains of bacteria. Additionally, the increasing patient preference for oral treatments, along with advancements in drug formulations and improved absorption mechanisms, are further propelling the growth of the oral sepsis therapeutic market.
The hospital pharmacies segment held the largest revenue share of 39.50% in 2024. Hospital pharmacies are central to the administration of sepsis treatments, as they are directly integrated into clinical settings where sepsis management takes place. These pharmacies play a critical role in the timely and accurate dispensing of medications required for sepsis management in hospitals, including antibiotics and supportive therapies. Their dominance is driven by the essential role hospitals play in the treatment of severe infections.
The online pharmacies is expected to grow at a considerable CAGR over the forecast period. The increasing acceptance of e-commerce platforms for pharmaceutical purchases, especially for non-urgent medications, is driving the expansion of online pharmacies in the market. While sepsis treatments typically require immediate clinical intervention, the growing trend of telemedicine and home healthcare, where patients are treated at home or in outpatient settings, is driving the demand for online pharmacy services for post-acute care and follow-up prescriptions. This segment is poised for rapid growth as convenience and accessibility continue to influence healthcare delivery.
North America sepsis therapeutics market dominated the global industry with a revenue share of 38.69% in 2024. This leadership is attributed to robust healthcare spending, a high level of awareness about sepsis, and the presence of major pharmaceutical companies. The demand for sepsis treatments is further supported by advancements in drug classes such as aminoglycosides, cephalosporins, and glycopeptides, with increasing adoption across hospital and retail pharmacies. The growing incidence of sepsis in the region, especially in the U.S., coupled with government policies encouraging innovative treatments, is propelling the market forward. The increasing usage of online pharmacies is also contributing to expanding access to therapies.
The U.S. sepsis therapeutics market accounted as the dominant region in North America registering a share of 90.23% in 2024. The rising number of sepsis cases, particularly due to hospital-acquired infections, is one of the key drivers of growth. The U.S. market benefits from advanced healthcare infrastructure, the presence of major pharmaceutical players, and the development of new therapies targeting resistant infections, such as glycopeptides and aminoglycosides. Moreover, with a shift toward more personalized medicine, parenteral drugs remain a crucial aspect of hospital care, while oral antibiotics are gaining traction in outpatient settings. Retail and online pharmacies are increasingly serving as distribution channels for these therapies.
Europe is experiencing steady growth in the sepsis therapeutics industry, driven by the rising incidence of sepsis across the region. Countries like Germany, France, and the UK are seeing an increased demand for sepsis treatments due to an aging population and the prevalence of chronic diseases that predispose patients to infections. Germany, in particular, is expected to drive the market with strong healthcare funding and a focus on precision medicine, which is facilitating the adoption of advanced therapies such as cephalosporins and glycopeptides. Hospital pharmacies in Europe are expanding, and there is growing adoption of online pharmacies to improve access to essential treatments. In the UK, the development of new drug classes to target resistant infections is also gaining momentum, enhancing the therapeutic options available.
The UK sepsis therapeutics market is anticipated to experience growth in the forthcoming years, primarily driven by the high incidence of sepsis and increasing awareness. According to recent statistics, the UK is one of the top countries in Europe where sepsis is a leading cause of mortality. The market is witnessing a rise in the use of advanced therapeutics, including oral antibiotics and intravenous treatments, with an increasing preference for cephalosporins and glycopeptides. Retail pharmacies and hospital pharmacies are the primary distribution channels. The UK’s National Health Service (NHS) is working towards integrating more advanced sepsis care protocols, enhancing accessibility to critical therapies through both physical and online pharmacies.
The sepsis therapeutics market in Germany is poised for significant growth over the forecast period, backed by strong healthcare funding, a robust diagnostics industry, and increasing incidence rates of sepsis, particularly in elderly populations. With a high prevalence of hospital-acquired infections, the demand for drugs like aminoglycosides and glycopeptides is rising. Germany’s advanced healthcare system supports the introduction of cutting-edge treatment modalities, with hospital pharmacies playing a crucial role in delivering intravenous therapies. Additionally, Germany’s emphasis on research and development in precision medicine is opening doors for personalized approaches in sepsis care, contributing to the overall market growth.
The France sepsis therapeutics market is expected to grow steadily during the forecast period, due to factors such as a rising aging population and increasing healthcare accessibility. France’s universal healthcare system ensures that patients have access to a wide range of therapeutic options, including oral and parenteral drugs from aminoglycoside, cephalosporin, and glycopeptide classes. The country is witnessing improvements in sepsis detection and management protocols, allowing for faster treatment and better outcomes. France is also focusing on public awareness campaigns that aim to reduce sepsis-related mortality, thus further stimulating demand for sepsis therapeutics.
The Asia Pacific sepsis therapeutics industry is experiencing rapid expansion, driven by rising healthcare expenditure, an aging population, and lifestyle changes that increase the incidence of sepsis. Countries like China, Japan, and India are seeing substantial increases in sepsis cases, particularly in urban areas where healthcare access is improving. The availability of sepsis treatments in oral and parenteral forms, including aminoglycosides and cephalosporins, is improving due to the increasing presence of global pharmaceutical companies. The market in China is particularly notable, where healthcare reforms are driving the adoption of advanced sepsis therapies, and online pharmacies are becoming a key distribution channel.
Japan’s sepsis therapeutics market is witnessing steady growth, largely supported by its advanced healthcare system and the country’s focus on precision medicine. The prevalence of sepsis in Japan, particularly among the aging population, is a key factor fueling market demand. Parenteral therapies, including cephalosporins and glycopeptides, are widely used in hospitals, while oral therapies are becoming more popular for outpatient care. The Japanese government is also investing in initiatives to improve sepsis care, including the integration of more advanced therapeutic protocols in hospitals and expanding access to medications through both retail and online pharmacies.
The sepsis therapeutics market in China is expected to grow significantly during the forecast period, driven by a rapidly aging population and the rise in lifestyle-related diseases, which are contributing to the higher incidence of sepsis. The Chinese government’s efforts to enhance healthcare infrastructure and expand insurance coverage are improving access to sepsis treatments, especially in rural areas. Parenteral antibiotics, such as aminoglycosides, remain crucial for treating severe cases of sepsis in hospital settings. Additionally, the rise of online pharmacies in China is enhancing access to oral antibiotics, making treatment more convenient and widespread.
The sepsis therapeutics industry in Latin America is growing rapidly, with increasing incidences of sepsis, particularly in countries like Brazil and Mexico. The rising number of hospitalizations and the region’s improving healthcare infrastructure are contributing to this growth. Brazil, with its expanding middle class and rising healthcare coverage, is seeing a shift toward advanced therapies, including aminoglycosides and cephalosporins. Brazil's hospital pharmacies are critical for treating severe sepsis cases, while retail and online pharmacies are becoming more important for providing outpatient treatments. Mexico's growing healthcare access is also boosting the demand for sepsis therapies, particularly as the country works to address its rising healthcare needs.
Brazil's sepsis therapeutics market is growing steadily, supported by an increasing number of sepsis cases, an aging population, and improving healthcare access. As Brazil's healthcare infrastructure expands and middle-class populations grow, more patients are gaining access to advanced sepsis treatments. The adoption of aminoglycosides, cephalosporins, and glycopeptides is increasing, with a significant shift toward using oral antibiotics for outpatient care and intravenous options in hospital settings. Retail pharmacies are seeing greater demand for these treatments, and online pharmacies are enhancing their role in reaching patients in remote areas.
The sepsis therapeutics industry in the Middle East and Africa is showing gradual growth, driven by rising sepsis incidence and significant investments in healthcare infrastructure. The region is particularly focused on addressing the increasing burden of lifestyle-related diseases, such as diabetes and obesity, which contribute to a higher risk of sepsis. In countries like Saudi Arabia, hospital pharmacies are central to administering intensive care therapies, including aminoglycosides and cephalosporins. However, retail pharmacies and online pharmacies are becoming increasingly important, offering broader access to treatments, particularly as healthcare systems continue to develop.
Saudi Arabia's sepsis therapeutics market is anticipated to grow steadily, driven by rising healthcare investments and a focus on improving sepsis care. The government is actively increasing funding for healthcare infrastructure and expanding insurance coverage, improving patient access to life-saving therapies. The use of intravenous antibiotics, including cephalosporins and glycopeptides, remains prevalent in hospitals, while oral antibiotics are increasingly being used in outpatient care settings. Online pharmacies are expanding in Saudi Arabia, making sepsis therapies more accessible to patients across the region.
Some key companies in the sepsis therapeutics market are AstraZeneca, Eli Lilly and Company, Pfizer Inc., etc. These companies are adopting various strategies to strengthen their market positions. Key players are actively expanding their presence in emerging markets through strategic collaborations and partnerships, as well as leveraging advancements in medical technology to improve treatment outcomes.
Product innovation and regulatory approvals are critical strategies employed by market leaders to maintain a competitive edge. Emerging players are focusing on niche areas such as personalized medicine and innovative delivery mechanisms to capture untapped opportunities in the supply chain. Furthermore, initiatives such as partnerships with research organizations and participation in clinical trials are helping companies to enhance their presence in the market.
The following are the leading companies in the sepsis therapeutics market. These companies collectively hold the largest market share and dictate industry trends.
View a comprehensive list of companies in the Sepsis Therapeutics Market
In September 2024, U.S. Senators Susan Collins, Chuck Schumer, and Bob Casey introduced the SEPSIS Act to enhance CDC efforts on sepsis care. The bill proposes an education campaign, improved pediatric sepsis data collection, collaboration with HHS and CMS on quality measures, and a sepsis outcome measure. It also includes a voluntary recognition program for hospitals with effective or improving sepsis programs
In May 2022, Sepsis Alliance launched the Sepsis Innovation Collaborative (SIC), a public-private initiative uniting experts from academia, healthcare, industry, and advocacy. SIC aims to advance innovative solutions for infection management, sepsis treatment, and emergency care, enhancing healthcare preparedness and response.
In August 2023, the CDC launched the Hospital Sepsis Program Core Elements initiative to help hospitals improve sepsis management. Modeled after antibiotic stewardship programs, it serves as a guide for organizing staff and resources to enhance sepsis care and boost survival rates.
Report Attribute |
Details |
Market size value in 2025 |
USD 4.18 billion |
Revenue forecast in 2030 |
USD 5.64 billion |
Growth rate |
CAGR of 6.18% from 2025 to 2030 |
Historical data |
2018 - 2024 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Drug class, route of administration, distribution channel, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Brazil; Argentina; South Africa; UAE; Saudi Arabia; Kuwait |
Key companies profiled |
Pfizer Inc.; GSK plc; AstraZeneca; Eli Lilly and Company; Astellas Pharma Inc.; Asahi Kasei Corporation; InflaRx GmbH; La Jolla Pharmaceutical Co.; T2 Biosystems Inc.; Aridis Pharmaceuticals Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global sepsis therapeutics market report based on drug class, route of administration, distribution channel, and region:
Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
Cephalosporin
Aminoglycosides
Glycopeptide
Other Drug Class
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
Parenteral
Oral
Others
Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global sepsis therapeutics market size was estimated at USD 3.94 billion in 2024 and is expected to reach USD 4.18 billion in 2025.
b. The global sepsis therapeutics market is expected to grow at a compound annual growth rate of 6.18% from 2025 to 2030 to reach USD 5.64 billion by 2030.
b. Based on drug class, the cephalosporin segment accounted for the largest revenue share of 60.70% in 2024, due to their broad-spectrum activity against gram-positive and gram-negative bacteria, which makes them a preferred choice in the treatment of sepsis.
b. Key players operating in the market are Pfizer Inc., GSK plc, AstraZeneca, Eli Lilly and Company, Astellas Pharma Inc., Asahi Kasei Corporation, InflaRx GmbH, La Jolla Pharmaceutical Co., T2 Biosystems Inc., and Aridis Pharmaceuticals Inc.
b. The rising incidence of sepsis, driven by factors such as hospital-acquired infections, surgical complications, and the increasing number of critically ill patients, is fueling demand for sepsis therapeutics. The growing awareness regarding the early detection and timely treatment of sepsis, along with advancements in diagnostic tools, is further contributing to market expansion.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."